This inventor holds 1 USPTO granted patent. Top assignee: Eli Lilly and Company. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Talbi Abelkader Kaoudi: Innovator in Diabetes Treatment
Introduction
Talbi Abelkader Kaoudi is a notable inventor based in Alcobendas, Spain. He has made significant contributions to the field of diabetes treatment through his innovative research and development efforts. His work focuses on creating effective solutions for managing type II diabetes mellitus.
Latest Patents
Kaoudi holds a patent for "Macrocyclic glucagon-like peptide 1 receptor agonists." This patent describes a compound of the formula or a pharmaceutically acceptable salt thereof, along with methods for using this compound to treat type II diabetes mellitus. This innovation represents a promising advancement in diabetes management.
Career Highlights
Kaoudi is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His role involves extensive research and development aimed at improving therapeutic options for patients with diabetes. His dedication to innovation has positioned him as a key player in the pharmaceutical industry.
Collaborations
Throughout his career, Kaoudi has collaborated with esteemed colleagues, including Douglas Linn Gernert and Graham Robert Cumming. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking treatments.
Conclusion
Talbi Abelkader Kaoudi's contributions to diabetes treatment through his patent and work at Eli Lilly and Company highlight his commitment to innovation in healthcare. His efforts continue to pave the way for advancements in the management of type II diabetes mellitus.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile